Obstetrics and Gynecology International,
Год журнала:
2025,
Номер
2025(1)
Опубликована: Янв. 1, 2025
Purpose:
This
study
aimed
to
evaluate
the
effect
of
COVID-19
infection
and
vaccination
on
all
menstrual
cycle
parameters
in
women
reproductive
age
group,
18-45
years,
at
a
tertiary
care
hospital.
Methods:
A
single-center,
descriptive
cross-sectional
was
done
from
January
2,
2023,
June
24,
2023.
Sampling
nonprobabilistic
purposeful.
Participants
were
recruited
via
calls,
in-person
interviews,
online
surveys.
total
931
participants
recruited,
which
141
eligible
for
study.
Descriptive
statistics
performed
variables.
Pearson's
chi-square
test
compare
categorical
variables
among
different
groups,
Wilcoxon
matched
pair
signed-rank
patterns
before
after
vaccination.
Simple
linear
regression
multiple
analysis
wherever
necessary.
p
<
0.05
considered
statistically
significant.
Results:
The
median
29
years.
Those
who
reported
abnormalities
mainly
group
18-27
(n
=
62,
44.0%),
resided
an
urban
locality
123,
87.2%),
employed
(full-time/part-time)
57,
40.4%).
Of
42
with
changes,
27
(64.3%)
experienced
changes
post-COVID-19
their
first
dose
15
(35.7%)
dose.
In
this
continue
experience
cycles.
Analysis
showed
that
having
severe
symptoms
more
likely
have
earlier
onset
(beta
-2.072,
p=0.040).
above-normal
BMI
increased
pain/cramps
during
menses
0.236,
p=0.0.013).
students/employed
-0.365,
p=0.001)
0.182,
p=0.024)
mood
swings/tension/irritability.
On
comparing
duration
postvaccination
it
found
latter
had
late-onset
short-term
effect,
while
former
early-onset
long-term
menses.
Conclusion:
Our
shows
there
is
evidence
irregularities
following
revealed
influence
cycles,
posing
higher
risk,
but
effects
menstruation
independent
one
another
are
be
studied
further.
International Journal of Women s Health,
Год журнала:
2022,
Номер
Volume 14, С. 395 - 404
Опубликована: Март 1, 2022
Background:
Since
the
emergence
of
COVID-19
vaccinations,
many
women
around
world
are
reporting
abnormalities
in
their
menstrual
periods
post-vaccination.
The
aim
this
study
is
to
investigate
prevalence
and
impact
after
vaccine
among
females
residing
within
Middle
East
North
Africa
(MENA).
Methods:
utilized
a
cross-sectional
online
self-administered
survey
from
July
2021
August
targeting
living
MENA
region
above
age
menarche
who
had
received
were
not
pregnant
or
lactating,
do
have
history
primary
ovarian
insufficiency,
hypothalamic
menopause,
undergone
hysterectomy.
was
distributed
regionally
via
social
media.
Results:
A
total
2269
included
our
study,
with
mean
34.3
±
8.5
years.
About
66.3%
participants
reported
symptoms
post-vaccination,
which
46.7%
experienced
them
first
dose.
However,
93.6%
participants,
resolved
2
months.
Vaccine
type
did
significantly
influence
incidence
(p
>
0.05).
Participants
confirmed
previous
infection
very
similar
percentage
compared
people
suspected
test
(67.5%,
66.8%,
respectively);
nevertheless,
those
general
side
effects
more
<
0.001).
Compared
pandemic
status,
Conclusion:
showed
possible
link
between
that
impacted
quality
life.
Keywords:
COVID-19,
MENA,
abnormalities,
cycle,
Open Medicine,
Год журнала:
2022,
Номер
17(1), С. 475 - 484
Опубликована: Янв. 1, 2022
We
investigated
menstrual
irregularities
after
the
first
and
second
doses
of
COVID-19
vaccine.
Women
answered
a
customised
online
questionnaire
(ClinicalTrial.gov
ID:
NCT05083065)
aimed
to
assess
vaccine
type,
phase
cycle
during
which
was
administered,
occurrence
doses,
how
long
this
effect
lasted.
excluded
women
with
gynaecological
non-gynaecological
diseases,
undergoing
hormonal
non-hormonal
treatments,
in
perimenopause
or
menopause,
as
well
those
who
had
irregular
cycles
last
12
months
before
administration.
According
our
data
analysis,
approximately
50-60%
reproductive-age
received
dose
reported
irregularities,
regardless
type
administered
The
seems
be
slightly
higher
(60-70%)
dose.
Menstrual
both
were
found
self-resolve
half
cases
within
two
months.
Based
on
these
results,
we
suggest
consider
elements
counselling
receive
vaccine,
letting
them
know
about
potential
temporary
self-limiting
subsequent
month(s).
Frontiers in Reproductive Health,
Год журнала:
2022,
Номер
4
Опубликована: Июль 25, 2022
COVID-19
vaccination
protects
against
the
potentially
serious
consequences
of
SARS-CoV-2
infection,
but
some
people
have
been
hesitant
to
receive
vaccine
because
reports
that
it
could
affect
menstrual
bleeding.
To
determine
whether
this
occurs
we
prospectively
recruited
a
cohort
79
individuals,
each
whom
recorded
details
at
least
three
consecutive
cycles,
during
which
time
they
received
one
dose
vaccine.
In
spontaneously
cycling
participants,
was
associated
with
delay
next
period,
change
reversed
in
subsequent
unvaccinated
cycles.
No
detected
those
taking
hormonal
contraception.
explore
hypotheses
about
mechanism
by
these
changes
occur,
retrospectively
larger
cohort,
1,273
who
had
kept
record
their
cycle
and
dates.
found
trend
toward
use
combined
contraception
being
protective
reporting
delayed
suggesting
following
may
be
mediated
perturbations
ovarian
hormones.
However,
were
unable
detect
clear
association
between
timing
within
changes.
Our
findings
suggest
can
lengthen
effect
Importantly,
find
returns
its
pre-vaccination
length
BMJ Medicine,
Год журнала:
2022,
Номер
1(1), С. e000297 - e000297
Опубликована: Сен. 1, 2022
Objectives
To
identify
whether
covid-19
vaccines
are
associated
with
menstrual
changes
in
order
to
address
concerns
about
cycle
disruptions
after
vaccination.
Design
Global,
retrospective
cohort
study
of
prospectively
collected
data.
Setting
International
users
the
tracking
application,
Natural
Cycles.
Participants
19
622
individuals
aged
18-45
years
lengths
24-38
days
and
consecutive
data
for
at
least
three
cycles
before
one
covid
(vaccinated
group;
n=14
936),
those
four
over
a
similar
time
period
(unvaccinated
n=4686).
Main
outcome
measures
The
mean
change
within
was
assessed
by
vaccination
group
menses
length
(mean
first
second
dose
vaccine
subsequent
cycle).
Mixed
effects
models
were
used
estimate
adjusted
difference
between
vaccinated
unvaccinated.
Results
Most
people
(n=15
713;
80.08%)
younger
than
35
years,
from
UK
(n=6222;
31.71%),
US
Canada
(28.59%),
or
Europe
(33.55%).
Two
thirds
(9929
(66.48%)
14
936)
received
Pfizer-BioNTech
(BNT162b2)
vaccine,
17.46%
(n=2608)
Moderna
(mRNA-1273),
9.06%
(n=1353)
Oxford-AstraZeneca
(ChAdOx1
nCoV-19),
1.89%
(n=283)
Johnson
&
(Ad26.COV2.S).
Individuals
who
had
less
day
increase
their
cycles,
compared
not
(0.71
(99.3%
confidence
interval
0.47
0.96)
dose;
0.56
(0.28
0.84)
dose).
larger
two
doses
(3.70
(2.98
4.42)).
One
vaccination,
per
(0.02
−0.10
0.14),
but
yet
(0.85
0.24
1.46))
unvaccinated
individuals.
Changes
did
differ
vaccine’s
mechanism
action
(mRNA,
adenovirus
vector,
inactivated
virus).
Menses
unaffected
Conclusions
Covid-19
is
small
likely
be
temporary
no
length.
Frontiers in Rehabilitation Sciences,
Год журнала:
2023,
Номер
4
Опубликована: Апрель 28, 2023
Long
COVID
disproportionately
affects
premenopausal
women,
but
relatively
few
studies
have
examined
COVID's
impact
on
female
reproductive
health.
We
conduct
a
review
of
the
literature
documenting
health
impacts
which
may
include
disruptions
to
menstrual
cycle,
gonadal
function,
ovarian
sufficiency,
menopause,
and
fertility,
as
well
symptom
exacerbation
around
menstruation.
Given
limited
research,
we
also
overlapping
associated
illnesses
including
myalgic
encephalomyelitis/chronic
fatigue
syndrome
(ME/CFS),
postural
orthostatic
tachycardia
(POTS),
connective
tissue
disorders
like
Ehlers-Danlos
(EDS),
endometriosis,
these
help
elucidate
conditions
in
COVID.
These
illnesses,
whose
patients
are
70%–80%
increased
rates
dysmenorrhea,
amenorrhea,
oligomenorrhea,
dyspareunia,
infertility,
vulvodynia,
intermenstrual
bleeding,
cysts,
uterine
fibroids
pelvic
congestion
syndrome,
gynecological
surgeries,
adverse
pregnancy
complications
such
preeclampsia,
maternal
mortality,
premature
birth.
Additionally,
symptoms
can
be
impacted
by
pregnancy,
menopause.
propose
priorities
for
future
research
healthcare
based
literature.
screening
comorbid
conditions;
studying
menopause
illness
progression;
uncovering
role
sex
differences
hormones
illnesses;
addressing
historical
inequities
that
contributed
detrimental
knowledge
gaps
this
patient
population.
Vaccine,
Год журнала:
2023,
Номер
41(36), С. 5271 - 5282
Опубликована: Июль 3, 2023
Many
signals
of
menstrual
disturbances
as
possible
side
effects
vaccination
against
COVID-19
have
been
reported.
Our
objective
was
to
compare
the
risk
before
and
after
among
women
aged
18-30
years
in
Oslo,
Norway.
We
used
electronic
questionnaires
collect
reports
from
3972
years,
participating
population-based
Norwegian
Young
Adult
Cohort.
examined
occurrence
(heavier
bleeding
than
usual,
prolonged
bleeding,
shorter
interval
between
menstruations,
longer
spot
bleedings,
stronger
pain
during
menstruation,
period
without
bleeding)
first
second
dose
vaccine.
Relative
risks
(RR)
according
were
estimated
using
a
self-controlled
case-series
design.
performed
additional
analyses
stratified
by
vaccine
brand,
contraception/hormone
use,
presence
gynecological
condition(s).
The
prevalence
any
disturbance
36.7%
last
cycle
prior
dose.
RR
for
heavier
usual
1.90
(95%
CI:
1.69-2.13)
1.84
(1.66-2.03)
Increased
menstruation
also
observed
both
doses.
RRs
did
not
differ
with
or
condition(s)
disturbances.
Menstrual
common
regardless
vaccination.
found
increased
vaccination,
particularly
pain.
In
future,
characteristics
should
be
included
trials.
Journal of Infection and Public Health,
Год журнала:
2023,
Номер
16(5), С. 697 - 704
Опубликована: Март 2, 2023
COVID
-
19
vaccine
can
lead
to
various
local
and
systemic
side
effects,
including
menstrual
irregularities
in
women.
There
is
no
robust
quantitative
evidence
of
the
association
between
irregularities.
A
meta-analysis
was
performed
estimate
pooled
prevalence
a
range
disorders
that
may
occur
women
following
vaccination.After
searching
for
epidemiological
studies,
we
systematically
on
PubMed/Medline,
EMBASE,
Science
Direct.
Sixteen
studies
were
finally
included
study.
We
estimated
corresponding
95
%
confidence
intervals
(CIs)
group
disorders,
menorrhagia,
polymenorrhea,
abnormal
cycle
length,
oligomenorrhea.
Heterogeneity
assessed
using
I2
statistic
Q
test.Overall,
menorrhagia
24.24
(pooled
%;
CI:
12.8-35.6
%).
The
polymenorrhea
16.2
prevalence:
10.7-21.6
length
relatively
lower
than
other
6.6
5.0-8.2
oligomenorrhea
22.7
(95
13.5-32.0
%).The
findings
indicate
oligomenorrhea,
most
common
after
vaccination.
also
suggest
high
proportion
suffer
from
Further
longitudinal
are
needed
confirm
causal
relationship
COVID-19
vaccination
BMJ Sexual & Reproductive Health,
Год журнала:
2024,
Номер
50(3), С. 212 - 225
Опубликована: Июнь 10, 2024
Menstrual
health
is
a
key
patient-reported
outcome
beyond
its
importance
as
general
indicator
of
and
fertility.
However,
menstrual
function
was
not
measured
in
the
clinical
trials
COVID-19
vaccines.
The
purpose
this
review
to
synthesise
existing
literature
on
relationship
between
vaccination
outcomes.